What are your top takeaways in GU Cancers from ASCO 2022?

1. Bladder cancer. Potential new non-muscle invasive bladder cancer immunotherapy with N-803, an IL-15 superagonist plus BCG. Abstract 4508. Demonstrated striking complete and durable remissions (70%), bladder preservations over 1-2 years of follow up (>90% cystectomy free survival), favorable toxic...

For urothelial cancer:

1. 4508 (Chamie et al.) Take home: intravesical BCG+N-803 showed impressive safety & efficacy data in BCG-unresponsive high-risk NMIBC and may seek regulatory approval in that setting; caveat is the single arm (not randomized) trial design; we noted a few differences in the des...

For bladder cancer only:

1. QUILT3032- IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) (Abstract: 4508): Combination N803 + BCG (both intravesical) was active in the CIS group (n=84, CR 71%, 1-year CR 61.6%, median DOR 26.6 mo) and the papillary gr...